Angioimmunoblastic T-cell lymphoma (AILT) and peripheral T-cell lymphoma, unspecified (PTCL-u) are relatively frequent subtypes of T-or natural killer cell lymphoma. To characterize the structural anomalies of chromosomes associated with these disorders, we here determined chromosome copy number alterations (CNAs) and loss of heterozygosity (LOH) at 455 000 single nucleotide polymorphism loci for clinical specimens of AILT (n ¼ 40) or PTCL-u (n ¼ 33). Recurrent copy number gain common to both conditions was detected on chromosomes 8, 9 and 19, whereas common LOH was most frequent for a region of chromosome 2. AILT-or PTCL-uspecific CNAs or LOH were also identified at 21 regions, some spanning only a few hundred base pairs. We also identified prognosis-related CNAs or LOH by several approaches, including Cox's proportional hazard analysis. Among the genes that mapped to such loci, a poor prognosis was linked to overexpression of CARMA1 at 7p22 and of MYCBP2 at 13q22, with both genes being localized within regions of frequent copy number gain. For a frequent LOH region at 2q34, we also identified IKAROS family zinc-finger 2 cDNAs encoding truncated proteins. Our data indicate that AILT and PTCL-u consist of heterogeneous subgroups with distinct transforming genetic alterations.
Introduction
Angioimmunoblastic T-cell lymphoma (AILT) and peripheral T-cell lymphoma, unspecified (PTCL-u) are relatively frequent subtypes of T-or natural killer (T/NK) cell lymphoma. 1 Although specific chromosomal translocations 2 and viral infections 3, 4 have been associated with subsets of T/NK cell lymphoma, the molecular pathogenesis of these disorders remains obscure in most cases. Furthermore, given that PTCL-u is diagnosed on the basis of patients not having other specific subtypes of PTCL, 5 it likely consists of heterogeneous subgroups of lymphoma. Prognosis of AILT and PTCL-u is generally poor, with a 5-year survival rate of B30%, 1 and standard treatment strategies for these conditions remain to be established. Characterization of the intrinsic genetic aberrations responsible for these two subtypes of T/NK cell lymphoma and the development of new classification schemes based on such molecular pathogenesis are thus important clinical goals.
In addition to nucleotide mutations and epigenetic abnormalities, structural changes of chromosomes, or chromosomal instability, are important in cancer development. 6 Gene amplification may promote the oncogenic activity of a subset of proto-oncogenes, such as MYC, ERBB2 and CCND1. Conversely, deletion or truncation of tumor suppressor genes may underlie inactivation of their function. Furthermore, loss of heterozygosity (LOH) is frequently observed in the tumor genome; this condition is characterized by the deletion of one allele of a gene either without (copy number (CN) ¼ 1) or with (CN ¼ 2, referred to as uniparental disomy) duplication of the remaining allele. Regions of the genome affected by LOH have been thought to harbor mutated or epigenetically silenced tumor suppressor genes. However, recent evidence indicates that these regions may also harbor activated oncogenes, as demonstrated for mutated JAK2 in myeloproliferative disorders. 7 Comparative genomic hybridization (CGH) has been applied to assess chromosome copy number alterations (CNAs) in AILT/PTCL-u. Renedo et al. 8 found the most common CN gain on X chromosome in T-cell non-Hodgkin's lymphoma. The same approach for PTCL-u with Zettl et al. 9 identified recurrent CN gains on chromosome 7q22-qter, and recurrent CN losses on 5q, 6q, 9p, 10q, 12q and 13q. Array-based CGH with a resolution of 4100 kb has also been used to examine AILT/PTCL-u, revealing recurrent CN gains of 11p11-q14, 19 and 22q in AILT, and of 8, 17 and 22q in PTCL-u. 10 Some inconsistency among these data may reflect the genetic heterogeneity in AILT/PTCL-u, and a low-resolution power in conventional or array-based CGH failed to pinpoint the genes essential to these CNAs.
Microarrays originally developed for typing of single nucleotide polymorphisms (SNPs) are now being applied to assess CNAs. Given that SNP-typing arrays are able both to assess heterozygosity or homozygosity along entire chromosomes and to determine the DNA quantity for each chromosome separately, 11 such arrays are able to measure chromosome CN and LOH simultaneously. Furthermore, the recent development of high-density SNP-typing arrays has allowed such measurements to be made at a resolution of o100 kb.
To identify characteristic genomic aberrations for AILT or PTCL-u in a high resolution, we have collected fresh specimens of AILT (n ¼ 40) and PTCL-u (n ¼ 33) and subjected them to hybridization with Affymetrix Mapping 50K Hind 240 microarrays (Affymetrix, Santa Clara, CA, USA). Application of bioinformatics to the resulting large data set revealed several novel genomic imbalances and candidate genes that may contribute to the pathogenesis of these two lymphomas.
Patients and methods

Clinical samples
Lymphoma specimens (70 from enlarged lymph nodes; 3 from extranodal tumors) were obtained from 73 patients (40 with AILT, 33 with PTCL-u) who attended Jichi Medical University Hospital or Fukushima Medical University Hospital between 1985 and 2004. The pathology of the specimens was reevaluated on the basis of the revised classification scheme of the World Health Organization (WHO). 5 All 73 specimens, which conformed with the WHO classification of AILT or PTCLu, were positive for the pan T-cell marker CD3 and negative for the monoclonal integration of human T-cell leukemia virusFI proviral DNA (data not shown). Mean age at diagnosis was 63 years (range, 19-89) and 67% of the patients were men. Most patients had been treated with cyclophosphamide-, doxorubicin-, vincristine-and prednisone-based regimens. Clinical characteristics of the study subjects are summarized in Supplementary 
SNP-typing arrays
Genomic DNA was extracted from the lymphoma specimens with the use of a QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA), digested with HindIII, ligated to the Adaptor-Hind (Affymetrix) and subjected to hybridization with Mapping 50K Hind 240 arrays (Affymetrix). SNP genotype calls were subsequently determined with GDAS software version 3.0 (Affymetrix) with a confidence score threshold of 0.05. Chromosome CN and the LOH likelihood score at each SNP site were calculated from the hybridization signal intensity and the SNP call with the use of CNAG 2.0 software (http:// www.genome.umin.jp). 12 Only CNAG data for autosomes were analyzed, and known copy number variation (CNV) loci 13, 14 were excluded from the analysis. We considered chromosome CNAs or LOH reliable only when X2 contiguous SNP probes yielded the same data. The mean probe signal intensity at diploid chromosomes was inferred from the data of control samples (in which most chromosomes would be expected to be diploid). Chromosome CN and LOH likelihood score data for all autosomal SNP sites are available on request.
Quantitative RT and real-time PCR analysis
Total RNA was isolated from specimens with the use of an RNeasy Mini column (Qiagen) and was subjected to reverse transcription (RT) with PowerScript reverse transcriptase (Clontech, Palo Alto, CA, USA). The amount of specific cDNAs was quantitated by real-time polymerase chain reaction (PCR) analysis with a QuantiTect SYBR Green PCR Kit (Qiagen). The amplification protocol consisted incubations at 94 1C for 15 s, 60 1C for 30 s and 72 1C for 60 s. The incorporation of the SYBR Green dye into the PCR products was monitored in real time with an ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA), thereby allowing determination of the threshold cycle (C T ) at which exponential amplification of products begins.
The relative abundance of the cDNAs of interest was calculated from the C T value for each cDNA and that for ACTB cDNA. The primer sequences for RT-PCR are shown in Supplementary 
Statistical analysis
Changes in chromosome CN or gene expression level were evaluated by Student's t-test. Hierarchical clustering of the data set was performed with GeneSpring 7.0 software (Agilent Technologies, Santa Clara, CA, USA). Overall survival was estimated by the Kaplan-Meier method and was compared with the logrank test. Multivariate analysis of survival was performed with the Cox proportional hazard model (stepwise regression approach). Unless indicated otherwise, a P-value o0.05 was considered statistically significant.
Results
Recurrent chromosome CNAs
Chromosome CN was computationally inferred at 55 700 SNP sites for all autosomes in 73 specimens of AILT or PTCL-u. Hierarchical clustering of all subjects on the basis of these CN profiles revealed that three quarters of the specimens had relatively stable chromosomes, whereas the remaining one quarter had CNAs of various sizes ( Figure 1a ). Common chromosome gain (CN X3 in X2 cases), for example, was identified at 28 243 SNP loci, whereas common chromosome loss (CN p1 in X2 cases) was detected at 6479 loci. The prognosis of study subjects with such CNAs (Figure 1a ) was significantly worse than that of those without them (Figure 1b) , indicative of linkage between these CNAs and the transformation process for AILT or PTCL-u.
In addition, frequent CNAs were readily identified in our data set. Highly recurrent chromosome amplification (CN X4 in X20 cases) was apparent at three distinct regions of 8q, 9p and 19q (Table 1 ). These regions were as small as 175 bp encompassing three contiguous SNP loci at 8q24.11 or 290 bp encompassing another three SNP loci at 19q13.43, demonstrating the high resolution of the SNP array-based CN analysis. Frequent copy number loss (CN of p1 in X4 cases), on the other hand, was identified at two distinct regions of 3q and 9p (Table 1) . Our CN data further revealed homozygous deletion at these two regions in some individuals (CN ¼ 0 in seven cases at 3q and in three cases at 9p).
Despite the similarity in the profiles for recurrent CNAs between AILT and PTCL-u (Table 1) , we examined whether there might be disease-specific CNAs for either of these disorders. Application of Student's t-test to the CN profiles for loci with frequent CNAs (those in X10% of subjects) resulted in the isolation of thirteen regions with a disease-dependent CNA (Supplementary Table 3 ).
Effects of CNAs on gene expression
To examine the relation between CNAs and gene expression, we performed quantitative RT-PCR analysis for genes that mapped within recurrent CNAs. The recurrent loss at 9p21.3 (Table 1) contains the genes for two important inhibitors of cyclindependent kinases, CDKN2A and CDKN2B, which are deleted or epigenetically silenced in a variety of cancer cells. 15 A decrease in DNA content at 9p21.3 was associated with a reduced level of expression of the genes that mapped to this locus: CDKN2A, CDKN2B and MTAP (left panel of Figure 2a ).
In addition to the recurrent CNAs shown in Table 1 , we also detected a frequent gain in CN at a locus of 7p22.3-22.2 in 30 out of the 73 patients; this locus contains the gene for caspase recruitment domain membrane-associated guanylate kinase protein 1 (CARMA1, GenBank accession no. NM_032415).
Overexpression of CARMA1 has been demonstrated in B-cell lymphoma and adult T-cell leukemia or lymphoma. 16, 17 As demonstrated in the right panel of Figure 2a , an increase in CN for CARMA1 was associated with an increase in the amount of the corresponding mRNA, albeit with a marginal statistical significance (P ¼ 0.053).
We then examined whether the altered expression of these genes influenced the survival of the affected individuals. Consistent with previous results for other hematologic malignancies, 18, 19 our data revealed a negative impact of a reduced level of CDKN2A expression on the clinical outcome of AILT or PTCL-u (Figure 2b ). In addition, individuals with AILT or PTCL-u showing an increase in CARMA1 expression had a poorer prognosis than did those without such an increase.
Recurrent LOH
We next calculated the LOH likelihood score 12 at each SNP site. By direct sequencing of some of the genomic regions with a high LOH likelihood score, we determined that a score of X20 was likely to be a reliable indicator of the presence of LOH (data not shown). We therefore used this value as a threshold for LOH in the following analyses.
Many (n ¼ 42 926) of the 55 700 SNP sites were found to have an LOH likelihood score of X20 in X2 patients in our cohort. Among these SNP sites, common LOH (LOH likelihood score of X20 in X10% of cases) was apparent at 3093 loci distributed throughout most chromosomes (Figure 3) . The most frequent region of LOH (LOH likelihood score of X20 in 22 samples) was an B440-kb region at 2q32.3 that includes 13 contiguous SNP loci.
We also screened for genomic loci whose LOH status was significantly linked to the diagnosis of AILT or PTCL-u. With a threshold P-value 0.001 (Student's t-test), we identified eight regions (each consisting of X2 contiguous SNP loci) that mapped to four distinct chromosomes ( Table 2 ). All of these Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; CN, copy number; CNA, copy number alterations; PTCL-u, peripheral T-cell lymphoma, unspecified.
a
The region with a frequent CN loss at the MDS1 locus is distinct from the reported CNV region within MDS1.
13,14 Chromosome copy number alterations in AILT and PTCL-u S-i Fujiwara et al disease-associated LOH loci had a normal chromosome CN of 2, indicative of uniparental disomy at these loci. Recently, aberrant expression of CD10 antigen has been reported for AILT cells. 20 We thus examined whether there are CNA/LOH, in our data set, related to such CD10-postive lymphoma cells. Immunohistostaining for CD10 was conducted among 64 cases in our cohort, revealing 21 cases positive for CD10 (Supplementary Table 1 ). Statistical analysis to detect CNAs associated with CD10-positive cases have identified one region of B220 kb at chromosome 7 containing GPR37 and POT1 genes (Student's t-test, Po0.001), whereas a similar analysis for the LOH status found nine distinct regions on chromosomes 1, 4, 5, 6, 7 and 18 (Supplementary Table 4 ).
Novel isoforms of IKZF2
To isolate additional candidate genes for AILT or PTCL-u, we performed nucleotide mutation screening of known cancerrelated genes located within the identified LOH regions. Extensive cDNA sequencing for these genes revealed a cDNA for a novel isoform of IKZF2, also known as Helios, in a subset of subjects. IKZF2 maps to chromosome 2q34, for which a high LOH likelihood score (X20) was identified in seven specimens (data not shown).
IKZF2 belongs to the IKAROS family of transcriptional factors, which are important regulators of lymphocyte development, 21, 22 and short isoforms of IKZF2 have been reported for the malignant cells of adult T-cell leukemia or lymphoma 23 and T-cell acute lymphoblastic leukemia. 24 In our cohort, RT-PCR amplification of the entire coding region of the IKZF2 mRNA detected a product in five of the seven study subjects with LOH at the IKZF2 locus (Figure 4a) . One of these products (from patient ID no. 1) was B1.3 kb in size and apparently smaller than the others. Nucleotide sequencing of this cDNA revealed that it did not contain exons 3 and 4 of IKZF2 (Figures 4b, c) and therefore encodes a protein that lacks 145 amino acids (including the first three zinc-finger domains) compared with the wild-type protein and has a Thr-to-Met substitution at amino-acid position 45 (the exon 2-5 boundary) (Figure 4b ). 
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We next examined whether the mRNA for this novel isoform of IKZF2 identified in the present study was also present in other patients or healthy individuals with the use of RT-PCR to amplify exons 2 to 7 of IKZF2 cDNA (Figure 4c ). Full-length cDNAs for IKZF2 variant 1 (GenBank accession no. NM_016260) and variant 2 (NM_001079526) were detected in all normal T cells and in most of the lymphoma samples (Figure 4d) . However, the cDNA for the short isoform was identified as a 414-bp product in seven patients (four with PTCLu, three with AILT), including the one in whom this isoform was initially identified. This latter individual (patient ID no. 1) did not yield RT-PCR products corresponding to wild-type IKZF2 cDNAs. Given that LOH was apparent at the IKZF2 locus in this patient, the lymphoma cells likely harbor only a single IKZF2 allele, which produces the truncated mRNA.
A novel cDNA fragment of 321 bp was further detected in the PTCL-u sample from patient ID no. 5 (Figure 4d ). Nucleotide sequencing of this product revealed it to encode an IKZF2 protein that lacks 175 amino acids corresponding to a portion of exon 3 and all of exons 4 to 6 (Figures 4b, c) .
Prognosis-related CNAs or LOH
To examine whether any of the CNAs or LOH regions identified in our data set are related to clinical outcome, we searched for prognosis-associated changes with several approaches. Given the many recurrent (at various frequencies) CNAs or LOH regions in the data set, we first examined whether some of these changes (observed in X5 samples) were preferentially present in patients who died within a year after diagnosis compared with those who survived for 41 year. For these potentially outcomerelated genomic regions, prognosis was then compared between the individuals with or without each CNA or LOH site with the logrank test. CN gain at chromosomes 2 or 5 was found to be linked to poor prognosis (Supplementary Table 5 ; Supplementary Figure 1a ). In addition, LOH at chromosomes 8 or 9 also had a negative impact on survival (Supplementary Table 5 ).
We next directly searched for genomic imbalances linked to poor prognosis by applying Cox's proportional hazard regression analysis to the chromosome CN profile for SNP loci with CNAs in X10% of subjects, resulting in the isolation of 12 regions with a P-value o0.05 (Supplementary Table 6 ; Supplementary Figure 1) . The b-score in the Cox analysis for all these regions was positive, indicating that CN gain at any of them is linked to a poor prognosis.
Further, Cox's analysis of CNAs only for the AILT data identified a CN gain at 13q22.3 that was significantly related (P ¼ 0.025) to poor clinical outcome (data not shown). This region spans only two contiguous SNP sites (corresponding to a distance of 237 bp) that map to a position 30 kb upstream of the MYC-binding protein 2 gene (MYCBP2, GenBank accession no. NM_015057). An increase in chromosome copy number at these SNP loci was further confirmed by quantitative PCR analysis (data not shown).
MYCBP2 is a large protein that binds specifically to Myc, 25 but whether it is involved in the transformation process of AILT is unknown. We detected a trend of an increase in the level of MYCBP2 expression in the specimens of AILT patients with a CN gain at this locus compared to that in those without such a gain (Figure 5a ), but without a statistical significance (Student's t-test, Chromosome copy number alterations in AILT and PTCL-u S-i Fujiwara et al P ¼ 0.23). Moreover, comparison of the survival of AILT patients with or without an increased expression of MYCBP2 revealed a significantly worse prognosis for the former (Figure 5b ). A poor prognosis for patients with increased MYCBP2 expression was also apparent for the entire AILT and PTCL-u cohort (Figure 5b ). These results suggest that MYCBP2 is a candidate for the transformation-associated gene that maps to the 13q22.3 locus. We also applied Cox's regression analysis to the LOH likelihood score data. For the PTCL-u data set, one region of B9.2 Mbp at chromosome 8 (nucleotide positions: 41 865 249-51 050 357) was identified as being significantly related to poor clinical outcome (Supplementary Figure 1c) .
Discussion
We have determined chromosome CN as well as LOH likelihood throughout the AILT or PTCL-u genome and have identified several novel recurrent and prognosis-related changes, some of which affect candidate genes for lymphomagenesis. In contrast to previous genomic analyses of T-cell lymphoma with CGH, [8] [9] [10] 26 our study based on SNP-typing arrays was able to identify many small regions (o100 kb) with CNAs or LOH in the genome of lymphoma cells.
We detected CNAs or LOH regions at a similar frequency in AILT and PTCL-u, consistent with previous data showing a common chromosome gain at 11q13 in the two disorders 10 or common CNAs in PTCL-u and ALK-negative anaplastic largecell lymphoma. 9 Few previous studies have described LOH in AILT or PTCL-u, possibly in part because of a high frequency of uniparental disomy in these conditions, as revealed in our data set (especially in the regions of recurrent LOH), that may be undetectable by conventional array-based CGH.
As tumor cell proportion in affected lymph nodes varies substantially among AILT/PTCL-u specimens, we tried to examine if such tumor cell proportion affects the CNA/LOH data. As shown in Supplementary Table 1, samples were classified into three subgroups; specimens with tumor cells composing o30% of lymph nodes were assigned to the 'L' group, whereas those with 30B60% were to the 'M' group, and those with X60% to the 'H' group. We then tested whether such tumor cell proportion was linked to the detection of chromosome unstable cases where aberrant chromosome copy numbers (other than 2) were found in 410% of the SNP probes. Although detection of such cases was not statistically different between the L and M subgroups, CNA-positive specimens in the H group was significantly more frequent than that in the M or L group (Fisher's exact test, P ¼ 0.002 for each comparison). Therefore, it is possible that tumor cell proportion in the specimens has significantly affected some parts of data set. However, it should be noted that (1) the high sensitivity of the CNA/LOHcalculation algorithm allows the detection of such changes among tumor samples contaminated with 70-80% of normal cells 27 and (2) tumor cell proportion in the affected lymph nodes of AILT/PTCL-u may remain stable throughout stage progression. 28, 29 Therefore, different frequency of CNA-positive cases may be an intrinsic property to the L/M/H subgroups of AILT/ PTCL-u. Large-scale CGH studies with purified AILT/PTCL-u tumor cells (by using laser-capture microdissection system, for instance) would help to address these issues.
One of the goals of our study was to identify novel diseaseassociated genes in AILT or PTCL-u. Among the recurrent CNA loci, we identified CARMA1 as a candidate gene for mediating the contribution of a 7p22 gain to lymphomagenesis. CARMA1 interacts with BCL10 and MALT1 and thereby mediates activation of nuclear factor (NF)-kB induced by stimulation of the T-or B-cell receptor. 10 Given that NF-kB frequently is activated and contributes to carcinogenesis in many tumor types, 30 activation of this transcription factor as a result of CARMA1 overexpression may also be important in disease progression and poor outcome of AILT or PTCL-u.
In addition, from a recurrent LOH locus, we identified cDNAs for novel short isoforms of IKZF2. Forced expression of full-length IKZF2 cDNA results in inhibition of T-cell development at an early stage. 31 A cDNA encoding a truncated, dominant-negative form of IKZF2 with impaired DNA-binding activity has been associated with adult T-cell leukemia or lymphoma 23 and T-cell acute lymphoblastic leukemia. 24 The development of T-cell lymphoma in mice expressing this dominant-negative form of IKZF2 provided further support for its clinical relevance. 31 Although the structure of our isoform of IKZF2 is different from that of the previously described short one, which lacks the second to fourth zinc-finger domains, 23 both forms have only one zinc-finger domain in the N-terminal DNA-binding region of the protein. Given that isoforms of IKAROS family members with fewer than two N-terminal zincfinger domains act in a dominant-negative manner, 32 both short isoforms of IKZF2 likely function as inhibitors of IKAROS family proteins. Given the transforming potential of a previously identified truncated form of IKZF2, 31 our data support the direct involvement of IKZF2 in transformation for a subset of AILT or PTCL-u. In addition, an increased level of MYCBP2 expression was associated with reduced survival time in AILT patients. The region of MYC that mediates binding to MYCBP2 is essential for the transactivation activity of MYC and is frequently mutated in Burkitt's and AIDS-related lymphomas. 25, 33 Given that such mutations in MYC impair its ubiquitination and degradation, 33 overexpression of MYCBP2 may similarly hinder the access of ubiquitination enzymes or the proteasome to MYC and thereby promote its accumulation.
As shown in Supplementary Table 1 , we have examined the expression of NK cell markers in the tumor cells. Expression of cell-surface CD56 was, for instance, tested with immunohistostaining procedures among 64 samples, and was found in only three cases. Similarly, presence of Epstein-Barr virus genome was analyzed among 65 cases, leading to the isolation of only two cases carrying the genome. It was thus difficult to draw statistically meaningful conclusions for CNA/LOH related to these small subgroups.
RefSeq genes may not be the only potential players in carcinogenesis. Large noncoding RNAs, for example, contribute to methylation of the genome, 34 whereas short noncoding RNAs, such as microRNAs, are implicated in regulation of cell growth and differentiation. 35 Such transcripts, despite their inability to synthesize proteins, may thus be involved in the development of AILT or PTCL-u. Given that the identification and annotation of these noncoding RNAs are still at an early stage, 36 ,37 many loci identified in our study may contain genes
for as yet undiscovered noncoding RNAs, and these transcripts may participate in carcinogenesis.
In conclusion, our study has provided a large-scale, detailed analysis of CNAs and LOH in AILT and PTCL-u, and has identified candidates for lymphomagenesis-related genes. Our data set should prove to be a useful platform for further definition, from the viewpoint of chromosome abnormalities, of these clinical entities.
